What is "evotec"

Evotec AG is a drug discovery and development partnership company providing drug discovery solutions to the pharmaceutical, biotechnology and academic sectors as well as to foundations and not-for-profit organisations. With a pool of highly experienced scientists, state-of-the-art technology platforms, first-class scientific operations and key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases, Evotec aims to develop best-in-class and first-in-class differentiated therapeutics – for collaborators or for its own internal pipeline development.

Evotec, founded in 1993, is a publicly listed stock corporation operating under German law. Since 2009, the Company has been listed in the Prime Standard at Frankfurt Stock Exchange and is a member of the TecDAX index.

Evotec is headquartered in Hamburg, Germany. In addition to Evotec’s site in Hamburg (Germany), major operating sites exist in Abingdon and Manchester (UK), Toulouse (France), Göttingen and Munich (Germany) and South San Francisco, Branford and Princeton (USA). Further offices in Germany, the USA, the UK, France and Japan handle Evotec’s international business development activities.

The Evotec Group employed 1,017 people at the end of June 2016.